Peringatan Keamanan

There is no information available regarding the LD50 values of ranibizumab. There is also limited clinical experience of ranibizumab overdose: concentrated doses as high as 2 mg ranibizumab in 0.05 mL have been administered to patients, with no additional unexpected adverse reactions that were observed.L38978

Ranibizumab

DB01270

biotech approved

Deskripsi

Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration.A2301, L38978 Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovascular (wet) age-related macular degeneration. The development of ranibizumab first began after bevacizumab, another anti-VEGF anticancer drug, was discovered to inhibit neovascularization and used in the off-label treatment of neovascular age-related macular degeneration for intravenous injection. In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use.A246399

Ranibizumab was initially approved by the FDA in 2006 A2301 and by the European Commission (EC) in 2007.L41429 It is marketed under the brand names LUCENTIS and SUSVIMO. BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada.L41399 In August 2022, other biosimilars CIMERLI, RAIVISIO, and RANOPTO were approved by the FDA, EC, and Health Canada respectively.L42625,L43513,L49141

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The estimated average vitreous elimination half-life is approximately nine days following intravitreal injection.[L38978] The half-life of ranibizumab implant is approximately 25 weeks.[L38983]
Volume Distribusi The apparent volume of the central compartment (Vd/F) is 2.77 L.[A246404] Ranibizumab is not shown to accumulate in serum.[L38983] Due to its small size from lacking the Fc region of an antibody, ranibizumab achieves enhanced diffusion into the retina and choroid.[A246399, A11475]
Klirens (Clearance) In patients with retinal vein occlusion or diabetic macular edema, the apparent clearance (CL/F) of ranibizumab was 24.8 L/day.[A246404]

Absorpsi

Ranibizumab rapidly penetrates through the retina to reach the choroid after intravitreal injection.A2298 Following monthly intravitreal administration of 0.5 mg ranibizumab in patients with neovascular (wet) age-related macular degeneration, the mean Cmax (±SD) was 1.7 (± 1.1) ng/mL.L38978 Following an implant insertion, the mean (±SD) Cmax of ranibizumab was 0.48 (±0.17) ng/mL and median Tmax was 26 days, with a range of one to 89 days.L38983

Metabolisme

The metabolism of ranibizumab has not been studied. Since it is a monoclonal antibody fragment, ranibizumab is expected to undergo catabolism.L38983

Rute Eliminasi

There is no information available.

Interaksi Obat

382 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Ranibizumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Ranibizumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Ranibizumab.
Estrone Estrone may increase the thrombogenic activities of Ranibizumab.
Estradiol Estradiol may increase the thrombogenic activities of Ranibizumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Ranibizumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Ranibizumab.
Mestranol Mestranol may increase the thrombogenic activities of Ranibizumab.
Estriol Estriol may increase the thrombogenic activities of Ranibizumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Ranibizumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Ranibizumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Ranibizumab.
Tibolone Tibolone may increase the thrombogenic activities of Ranibizumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Ranibizumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Ranibizumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Ranibizumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Ranibizumab.
Zeranol Zeranol may increase the thrombogenic activities of Ranibizumab.
Equol Equol may increase the thrombogenic activities of Ranibizumab.
Promestriene Promestriene may increase the thrombogenic activities of Ranibizumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Ranibizumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Ranibizumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Ranibizumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Ranibizumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Ranibizumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Ranibizumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Ranibizumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Ranibizumab.
Formononetin Formononetin may increase the thrombogenic activities of Ranibizumab.
Estetrol Estetrol may increase the thrombogenic activities of Ranibizumab.
Pamidronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Pamidronic acid.
Zoledronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Zoledronic acid.
Alendronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Alendronic acid.
Ibandronate The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Ibandronate.
Clodronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Clodronic acid.
Risedronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Risedronic acid.
Etidronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Etidronic acid.
Tiludronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Tiludronic acid.
Incadronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Incadronic acid.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Ranibizumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Ranibizumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Ranibizumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Ranibizumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Ranibizumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Ranibizumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Ranibizumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Ranibizumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Ranibizumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Ranibizumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Ranibizumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Ranibizumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ranibizumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Ranibizumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Ranibizumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ranibizumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Ranibizumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Ranibizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Ranibizumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Ranibizumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Ranibizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Ranibizumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Ranibizumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Ranibizumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Ranibizumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Ranibizumab.
Galiximab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Galiximab.
Pexelizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Pexelizumab.
Afelimomab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Afelimomab.
Epratuzumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Epratuzumab.
Bectumomab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Bectumomab.
Oregovomab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Oregovomab.
IGN311 The risk or severity of adverse effects can be increased when Ranibizumab is combined with IGN311.
Adecatumumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Adecatumumab.
Labetuzumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Labetuzumab.
Matuzumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Matuzumab.
Fontolizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Fontolizumab.
Bavituximab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Bavituximab.
CR002 The risk or severity of adverse effects can be increased when Ranibizumab is combined with CR002.
Rozrolimupab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Rozrolimupab.
Girentuximab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Girentuximab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Obiltoxaximab.
XTL-001 The risk or severity of adverse effects can be increased when Ranibizumab is combined with XTL-001.
NAV 1800 The risk or severity of adverse effects can be increased when Ranibizumab is combined with NAV 1800.
Briakinumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Briakinumab.
Otelixizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Otelixizumab.
AMG 108 The risk or severity of adverse effects can be increased when Ranibizumab is combined with AMG 108.
Iratumumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Iratumumab.
Enokizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Enokizumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Ramucirumab.
Farletuzumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Farletuzumab.
Veltuzumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Veltuzumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Ustekinumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Ranibizumab is combined with Trastuzumab emtansine.
PRO-542 The risk or severity of adverse effects can be increased when Ranibizumab is combined with PRO-542.
TNX-901 The risk or severity of adverse effects can be increased when Ranibizumab is combined with TNX-901.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Ranibizumab is combined with Inotuzumab ozogamicin.
RI 624 The risk or severity of adverse effects can be increased when Ranibizumab is combined with RI 624.
Stamulumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with MYO-029.
CT-011 The risk or severity of adverse effects can be increased when Ranibizumab is combined with CT-011.
Leronlimab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Leronlimab.

Target Protein

Vascular endothelial growth factor A, long form VEGFA

Referensi & Sumber

Artikel (PubMed)
  • PMID: 18046235
    Gaudreault J, Fei D, Beyer JC, Ryan A, Rangell L, Shiu V, Damico LA: Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 2007 Nov-Dec;27(9):1260-6.
  • PMID: 18035187
    Kourlas H, Abrams P: Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther. 2007 Sep;29(9):1850-61.
  • PMID: 31335082
    Vaidyanathan U, Moshirfar M: Ranibizumab .
  • PMID: 17714704
    Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M: Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007 Oct;85(4):425-30. doi: 10.1016/j.exer.2007.05.008. Epub 2007 Jun 13.
  • PMID: 19668384
    Spitzer MS, Ziemssen F, Bartz-Schmidt KU, Gelisken F, Szurman P: Treatment of age-related macular degeneration: focus on ranibizumab. Clin Ophthalmol. 2008 Mar;2(1):1-14.
  • PMID: 34860956
    Akiyode O, Dunkelly-Allen N: Ranibizumab: A Review of Its Use in the Treatment of Diabetic Retinopathy in Patients With Diabetic Macular Edema. J Pharm Technol. 2016 Feb;32(1):22-28. doi: 10.1177/8755122515599552. Epub 2015 Aug 12.

Contoh Produk & Brand

Produk: 24 • International brands: 0
Produk
  • 1 Ranivisio
    Injection, solution • 10 mg/ml • Intravitreal • EU • Approved
  • Byooviz
    Solution • 10 mg / mL • Intravitreal • Canada • Approved
  • Byooviz
    Injection, solution • 10 mg/1mL • Intravitreal • US • Approved
  • Byooviz
    Injection, solution • 10 mg/ml • Intravitreal • EU • Approved
  • Byooviz
    Injection, solution • 10 mg/ml • Intravitreal • EU • Approved
  • Cimerli
    Injection, solution • 0.3 mg/0.05mL • Intravitreal • US • Approved
  • Cimerli
    Injection, solution • 0.5 mg/0.05mL • Intravitreal • US • Approved
  • Cimerli
    Injection, solution • 0.3 mg/0.05mL • Intravitreal • US • Approved
Menampilkan 8 dari 24 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul